… unresectable stage III or IV squamous cell carcinoma of the head and neck (SCCHN). The
… , we report the results of a randomised phase II trial comparing TPF with TP + cetuximab (C). …

… /cetuximab or carboplatin/cetuximab in first line. Patients who received cisplatin/cetuximab-…
OS compared to patients treated with carboplatin/cetuximab (13.7 months vs 9.5 months, …

… Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for
recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a …

… in patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). …
and safety of 5-fluorouracil/cisplatin/cetuximab (FPE) therapy as a candidate regimen for …

Background Based on a potential synergistic effect of anti–PD-L1 avelumab plus cetuximab
and radiotherapy (RT), this combination was tested in a randomized phase III trial against 2 …

… NKG2A blockade promotes anti-tumor immunity and may provide additional activity to
cetuximab and durvalumab. We report here the safety and efficacy of monalizumab and cetuximab …

… in recurrent metastatic head and neck cancer by focusing on a single … ) head and neck
squamous cell carcinoma (HNSCC) who received systemic chemotherapy with weekly cetuximab …

… controlled trials (RCTs) to revaluate the efficacy and safety of cetuximab vs. cisplatin
combined with radiotherapy in patients of head and neck squamous cell carcinoma (HNSCC). …

… Squamous cell carcinoma of the head and neck (SCCHN) is one of the most frequently
diagnosed cancers worldwide. More than half of patients diagnosed with locally advanced …

… In this study, the long-term cellular outcome of prolonged cetuximab … a head and neck
squamous cell carcinoma cell line constitutively expressing a fluorescent ubiquitination-based cell …